Semih Başcı

8PUBLICATIONS
43CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)HaematologyRespiratory diseasesAnaesthesiologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Oct 16, 2026
Anthracycline-Free FLA-VEN with or Without Midostaurin in Newly Diagnosed Intermediate- and Adverse-Risk AML: A Single-Center Retrospective Study.

|Jul 20, 2024
Early Tapering of Cyclosporine Is Feasible in Haploidentical Stem Cell Transplantation: A Single Center Experience.

Samet Yaman, Semih Başci, Ersin Bozan

|Sep 13, 2021
Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients.

Bahar Uncu Ulu, Mehmet Sinan Dal, İpek Yönal Hindilerden

|Jun 10, 2021
Patients with hematologic cancers are more vulnerable to COVID-19 compared to patients with solid cancers.

Semih Başcı, Naim Ata, Fevzi Altuntaş

|May 06, 2021
COVID-19 clinical course and blood groups: Turkish population-based study

Mehmet Sinan Dal, Naim Ata, Fevzi Altuntaş

|Nov 25, 2020
Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: a single center experience

Hikmettullah Batgi, Semih Başcı, Mehmet Sinan Dal

Pageof 2

Frequent Collaborators

3 joint publications

Mehmet Sinan Dal

3 joint publications

Tuğçe Nur Yiğenoğlu

3 joint publications

Fevzi Altuntaş

2 joint publications

Merih Kızıl Çakar